Skip to main content
. 2019 Apr;11(4):1347–1354. doi: 10.21037/jtd.2019.03.61

Figure 3.

Figure 3

PFS and OS between gefitinib and erlotinib treatment groups in patients without CNS metastasis before EGFR-TKI treatment. PFS, progression free survival; OS, overall survival; CNS, central nervous system; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.